Study to Assess Sarilumab in Halting Progression of Morphea

NCT03679845 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Difficulty in recruiting patients

Conditions

Morphea, Plaque Form

Interventions

DRUG: Sarilumab

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]